Gastrointestinal symptomsparticularly nausea, vomiting, diarrhoea, and constipationare the most frequently reported adverse effects of GLP-1 receptor agonists, occurring in 2050% of patients depending on the specific agent and dose according to clinical trials and SmPC data
A GLP-1 agonist (more precisely a GLP-1 receptor agonist) is a medication that mimics the effects of the natural hormone
BMI above 40 (class 3 obesity) The highest starting BMI group can achieve enormous absolute weight loss with GLP-1 therapy
This model suggests that antitumor effects may be dependent on concurrent administration and not mediated solely by weight loss
A little preparation goes a long way
Online Exclusives GLP-1 Drugs and The Pharma Supply Chain Overcoming distribution hurdles to meet demand, cold chain solutions and strategies, and streamlining the supply chain to mitigate rising costs